Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' Przepiorka, D' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 198 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Przepiorka, D
      The CDC Guidelines for Prevention of Infections: rule with reason

      CYTOTHERAPY
    2. Savary, CA; Grazziutti, ML; Przepiorka, D; Tomasovic, SP; McIntyre, BV; Woodside, DG; Pellis, NR; Pierson, DL; Rex, JH
      Characteristics of human dendritic cells generated in a microgravity analog culture system

      IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL
    3. Bibawi, S; Abi-Said, D; Fayad, L; Anderlini, P; Ueno, NT; Mehra, R; Khouri, I; Giralt, S; Gajewski, J; Donato, M; Claxton, D; Braunschweig, I; van Besien, K; Andreeff, M; Andersson, BS; Estey, EH; Champlin, R; Przepiorka, D
      Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia

      AMERICAN JOURNAL OF HEMATOLOGY
    4. Hsu, B; May, R; Carrum, G; Krance, R; Przepiorka, D
      Use of antithymocyte globulin for treatment of steroid-refractory acute graft-versus-host disease: an international practice survey

      BONE MARROW TRANSPLANTATION
    5. Grazziutti, M; Przepiorka, D; Rex, JH; Braunschweig, I; Vadhan-Raj, S; Savary, CA
      Dendritic cell-mediated stimulation of the in vitro lymphocyte response toAspergillus

      BONE MARROW TRANSPLANTATION
    6. Kornblau, SM; Stiouf, I; Snell, V; Przepiorka, D; Stephens, LC; Champlin, R; Marini, FC
      Preemptive control of graft-versus-host disease in a murine allogeneic transplant model using retrovirally transduced murine suicidal lymphocytes

      CANCER RESEARCH
    7. Przepiorka, D; Anderlini, P; Saliba, R; Cleary, K; Mehra, R; Khouri, I; Huh, YO; Giralt, S; Braunschweig, I; van Besien, K; Champlin, R
      Chronic graft-versus-host disease after allogeneic blood stem cell transplantation

      BLOOD
    8. Giralt, S; Thall, PF; Khouri, I; Wang, XM; Braunschweig, I; Ippolitti, C; Claxton, D; Donato, M; Bruton, J; Cohen, A; Davis, M; Andersson, BS; Anderlini, P; Gajewski, J; Kornblau, S; Andreeff, M; Przepiorka, D; Ueno, NT; Molldrem, J; Champlin, R
      Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation

      BLOOD
    9. Przepiorka, D; Smith, TL; Folloder, J; Anderlini, P; Chan, KW; Korbling, M; Lichtiger, B; Norfleet, F; Champlin, R
      Controlled trial of filgrastim for acceleration of neutrophil recovery after allogeneic blood stem cell transplantation from human leukocyte antigen-matched related donors

      BLOOD
    10. Braunschweig, I; Mirza, NQ; Rondon, G; Lauppe, J; Mehra, R; Gajewski, J; Korbling, M; Huh, YO; Geisler, D; Gee, AP; Champlin, R; Przepiorka, D
      High CD34 cell doses do not worsen regimen-related toxicity or early mortality after autologous blood stem cell transplantation for breast cancer

      CYTOTHERAPY
    11. Przepiorka, D; Saliba, R; Cleary, K; Fischer, H; Tonai, R; Fritsche, H; Khouri, IF; Folloder, J; Ueno, NT; Mehra, R; Ippoliti, C; Giralt, S; Gajewski, J; Donato, M; Claxton, D; Braunschweig, I; van Besien, K; Anderlini, P; Andersson, BS; Champlin, R
      Tacrolimus does not abrogate the increased risk of acute graft-versus-hostdisease after unrelated-donor marrow transplantation with allelic mismatching at HLA-DRB I and HLA-DQB I

      BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
    12. Heslop, H; Rooney, C; Brenner, M; Krance, R; Carrum, G; Gahn, B; Bollard, C; Khan, S; Gee, A; Popat, U; Gresik, M; Przepiorka, D; Kuehnle, I; Grilley, B
      Clinical protocol - Administration of neomycin resistance gene-marked EBV-specific cytotoxic T-lymphocytes as therapy for patients receiving a bone marrow transplant for relapsed EBV-positive Hodgkin disease

      HUMAN GENE THERAPY
    13. Tran, HT; Madden, T; Petropoulos, D; Worth, LL; Felix, EA; Sprigg-Saenz, HA; Choroszy, M; Danielson, M; Przepiorka, D; Chan, KW
      Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies

      BONE MARROW TRANSPLANTATION
    14. Murray, JL; Przepiorka, D; Ioannides, CG
      Clinical trials of HER-2/neu-specific vaccines

      SEMINARS IN ONCOLOGY
    15. Nash, RA; Antin, JH; Karanes, C; Fay, JW; Avalos, BR; Yeager, AM; Przepiorka, D; Davies, S; Petersen, FB; Bartels, P; Buell, D; Fitzsimmons, W; Anasetti, C; Storb, R; Ratanatharathorn, V
      Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors

      BLOOD
    16. Przepiorka, D; Kernan, NA; Ippoliti, C; Papadopoulos, EB; Giralt, S; Khouri, I; Lu, JG; Gajewski, J; Durett, A; Cleary, K; Champlin, R; Andersson, BS; Light, S
      Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease

      BLOOD
    17. Gajewski, JL; Nimer, S; Saliba, RM; Thomas, M; Przepiorka, D; Giralt, S; von Besien, K; Mehra, R; Andersson, B; Chan, KW; Ippoliti, C; Warkinten, D; Feig, S; Territo, M; Schiller, G; Lebkowski, J; Moseley, AM; Lloyd, K; von Hoeff, M; Okarma, T; Champlin, R
      Long-term outcome of a Phase II study of BM transplants, partially depleted ex-vivo of CD5-positive and CD8-positive T-lymphocytes in unrelated and related donor 1 antigen mismatched recipients

      CYTOTHERAPY
    18. Przepiorka, D; Lu, JG; Anderlini, P; Korbling, M; Donato, M; Champlin, R; Gee, AP; van Vlasselaer, P
      Debulking blood stem cell collections by density gradient centrifugation in a closed-vessel system

      CYTOTHERAPY
    19. Przepiorka, D; van Besien, K; Khouri, I; Hagemeister, F; Samuels, B; Folloder, J; Ueno, NT; Molldrem, J; Mehra, R; Korbling, M; Giralt, S; Gajewski, J; Donato, M; Cleary, K; Claxton, D; Braunschweig, I; Andersson, B; Anderlini, P; Champlin, R
      Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma

      ANNALS OF ONCOLOGY
    20. Worth, LL; Tran, H; Petropoulos, D; Culbert, SC; Mullen, CA; Roberts, WM; Przepiorka, D; Chan, KW
      Hematopoietic stem cell transplantation for childhood myeloid malignanciesafter high-dose thiotepa, busulfan and cyclophosphamide

      BONE MARROW TRANSPLANTATION
    21. Przepiorka, D; Khouri, I; Ippoliti, C; Ueno, NT; Mehra, R; Korbling, M; Giralt, S; Gajewski, J; Fischer, H; Donato, M; Cleary, K; Claxton, D; Chan, KW; Braunschweig, I; van Besien, K; Andersson, BS; Anderlini, P; Champlin, R
      Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation

      BONE MARROW TRANSPLANTATION
    22. Maltazou, H; Whimbey, E; Abi-Said, D; Przepiorka, D; Champlain, R; Goodrich, JM
      Cytomegalovirus disease in adult marrow transplant recipients receiving ganciclovir prophylaxis: a retrospective study

      BONE MARROW TRANSPLANTATION
    23. Przepiorka, D; Devine, SM; Fay, JW; Uberti, JP; Wingard, JR
      Practical considerations in the use of tacrolimus for allogeneic marrow transplantation

      BONE MARROW TRANSPLANTATION
    24. Przepiorka, D; Petropoulos, D; Mullen, CA; Danielson, M; Mattewada, V; Chan, KW
      Tacrolimus for prevention of graft-versus-host disease after mismatched unrelated donor cord blood transplantation

      BONE MARROW TRANSPLANTATION
    25. Przepiorka, D; Khouri, I; Thall, P; Mehra, R; Lee, MS; Ippoliti, C; Giralt, S; Gajewski, J; van Besien, K; Andersson, B; Korbling, M; Deisseroth, AB; Champlin, R
      Thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced chronic myelogenous leukemia

      BONE MARROW TRANSPLANTATION
    26. Garderet, L; Snell, V; Przepiorka, D; Schenk, T; Lu, JG; Marini, F; Gluckman, E; Andreeff, M; Champlin, RE
      Effective depletion of alloreactive lymphocytes from peripheral blood mononuclear cell preparations

      TRANSPLANTATION
    27. Przepiorka, D; Smith, TL; Folloder, J; Khouri, I; Ueno, NT; Mehra, R; Korbling, M; Huh, YO; Giralt, S; Gajewski, J; Donato, M; Cleary, K; Claxton, D; Braunschweig, I; van Besien, K; Andersson, BS; Anderlini, P; Champlin, R
      Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation

      BLOOD
    28. Guardiola, P; Anderson, JE; Bandini, G; Cervantes, F; Runde, V; Arcese, W; Bacigalupo, A; Przepiorka, D; O'Donnell, MR; Polchi, P; Buzyn, A; Sutton, L; Cazals-Hatem, D; Sale, G; de Witte, T; Deeg, HJ; Gluckman, E
      Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: A European group for blood and marrow transplantation, Societe Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center collaborative study

      BLOOD
    29. PRZEPIORKA D; SRIVASTAVA PK
      HEAT-SHOCK-PROTEIN PEPTIDE COMPLEXES AS IMMUNOTHERAPY FOR HUMAN CANCER

      Molecular medicine today
    30. RAHMAN Z; KAVANAGH J; CHAMPLIN R; GILES R; HANANIA E; FU SQ; ZU ZF; MEHRA R; HOLMES F; KUDELKA A; CLAXTON D; VERSCHRAEGEN C; GAJEWSKI J; ANDREEFF M; HEIMFELD S; BERENSON R; ELLERSON D; CALVERT L; MECHETNER E; HOLZMAYER T; DAYNE A; HAMER J; BACHIER C; OSTROVE J; PRZEPIORKA D; BURTNESS B; COTE R; BAST R; HORTOBAGYI G; DEISSEROTH A
      CHEMOTHERAPY IMMEDIATELY FOLLOWING AUTOLOGOUS STEM-CELL TRANSPLANTATION IN PATIENTS WITH ADVANCED BREAST-CANCER

      Clinical cancer research
    31. KHOURI IF; KEATING M; KORBLING M; PRZEPIORKA D; ANDERLINI P; OBRIEN S; GIRALT S; IPPOLITI C; VONWOLFF B; GAJEWSKI J; DONATO M; CLAXTON D; UENO N; ANDERSSON B; GEE A; CHAMPLIN R
      TRANSPLANT-LITE - INDUCTION OF GRAFT-VERSUS-MALIGNANCY USING FLUDARABINE-BASED NONABLATIVE CHEMOTHERAPY AND ALLOGENEIC BLOOD PROGENITOR-CELL TRANSPLANTATION AS TREATMENT FOR LYMPHOID MALIGNANCIES

      Journal of clinical oncology
    32. UENO NT; RONDON G; MIRZA NQ; GEISLER DK; ANDERLINI P; GIRALT SA; ANDERSSON BS; CLAXTON DF; GAJEWSKI JL; KHOURI IF; KORBLING M; MEHRA RC; PRZEPIORKA D; RAHMAN Z; SAMUELS BI; VANBESIEN K; HORTOBAGYI GN; CHAMPLIN RE
      ALLOGENEIC PERIPHERAL-BLOOD PROGENITOR-CELL TRANSPLANTATION FOR POOR-RISK PATIENTS WITH METASTATIC BREAST-CANCER

      Journal of clinical oncology
    33. Khouri, IF; Romaguera, J; Kantarjian, H; Palmer, JL; Pugh, WC; Korbling, M; Hagemeister, F; Samuels, B; Rodriguez, A; Giralt, S; Younes, A; Przepiorka, D; Claxton, D; Cabanillas, F; Champlin, R
      Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: An active regimen for aggressive mantle-cell lymphoma

      JOURNAL OF CLINICAL ONCOLOGY
    34. PRZEPIORKA D; GIRALT S; KHOURI I; CHAMPLIN R; BUESORAMOS C
      ALLOGENEIC MARROW TRANSPLANTATION FOR MYELOPROLIFERATIVE DISORDERS OTHER THAN CHRONIC MYELOGENOUS LEUKEMIA - REVIEW OF 40 CASES

      American journal of hematology
    35. SAVARY CA; GRAZZIUTTI ML; MELICHAR B; PRZEPIORKA D; FREEDMAN RS; COWART RE; COHEN DM; ANAISSIE EJ; WOODSIDE DG; MCINTYRE BW; PIERSON DL; PELLIS NR; REX JH
      MULTIDIMENSIONAL FLOW-CYTOMETRIC ANALYSIS OF DENDRITIC CELLS IN PERIPHERAL-BLOOD OF NORMAL DONORS AND CANCER-PATIENTS

      Cancer immunology and immunotherapy
    36. PRZEPIORKA D; KERNAN N; IPPOLITI C; PAPADOPOULOS E; GIRALT S; KHOURI I; LU J; GAJEWSKI J; DURETT A; CLEARY R; CHAMPLIN R; ANDERSSON B; LIGHT S
      PHASE-II STUDY OF DACLIZUMAB FOR TREATMENT OF ACUTE GRAFT-VS-HOST DISEASE

      Experimental hematology
    37. GAJEWSKI J; RONDON G; MIRZA N; MEHRA R; DONATO M; ANDERLINI P; KORBLING M; THERIALT R; KHOURI I; GIRALT S; BUZDAR A; UENO N; PRZEPIORKA D; ANDERSSON B; DURRETT A; SALIBA R; BRUTON J; RAHMAN Z; IPPOLITI C; HORTABAQYI G; RABER M; BAST R; CHAMPLIN R
      PRELIMINARY-RESULTS OF A RANDOMIZED TRIAL COMPARING INTENSIVE CHEMOTHERAPY WITH GROWTH-FACTOR (GF) OR PERIPHERAL-BLOOD PROGENITOR (PBPC) CELL MOBILIZATION TO GROWTH-FACTOR ALONE FOR HEMATOPOIETIC RESCUE AFTER HIGH-DOSE CHEMOTHERAPY (HDC)

      Experimental hematology
    38. NARVIOS AB; PRZEPIORKA D; TARRAND J; CHAN KW; CHAMPLIN R; LICHTIGER B
      TRANSFUSION SUPPORT USING FILTERED UNSCREENED BLOOD PRODUCTS FOR CYTOMEGALOVIRUS-NEGATIVE ALLOGENEIC MARROW TRANSPLANT RECIPIENTS

      Bone marrow transplantation
    39. KIANG E; TESAVIBUL N; YEE R; KELLAWAY J; PRZEPIORKA D
      THE USE OF TOPICAL CYCLOSPORINE-A IN OCULAR GRAFT-VERSUS-HOST-DISEASE

      Bone marrow transplantation
    40. KORBLING M; PRZEPIORKA D; ANDERLINI P; CHAMPLIN R
      ALLOGENEIC BLOOD STEM-CELL TRANSPLANTATION - A REPLACEMENT FOR BONE-MARROW TRANSPLANTATION

      Bone marrow transplantation
    41. PRZEPIORKA D; IPPOLITI C; KHOURI I; ANDERLINI P; FOLLODER J; UENO N; MEHRA R; GIRALT S; GAJEWSKI J; CLEARY K; CLAXTON D; CHAMPLIN R; ANDERSSON B; KORBLING M
      IMPACT OF PROPHYLAXIS REGIMEN ON THE INCIDENCE OF ACUTE GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC BLOOD STEM-CELL TRANSPLANTATION

      Bone marrow transplantation
    42. ANDERLINI P; PRZEPIORKA D; KORBLING M; CHAMPLIN R
      BLOOD STEM-CELL PROCUREMENT - DONOR SAFETY ISSUES

      Bone marrow transplantation
    43. ANDERLINI P; ANDERSSON B; GAJEWSKI J; GIRALT S; MEHRA R; CLAXTON D; UENO N; KHOURI I; PRZEPIORKA D; DONATO M; KORBLING M; CHAMPLIN R
      ALLOGENEIC STEM-CELL TRANSPLANTATION FOR ADVANCED HODGKINS-DISEASE - THE ANDERSON,M.D. EXPERIENCE

      Bone marrow transplantation
    44. KHOURI IF; ROMAGUERA J; PALMER JL; PUGH WC; KORBLING M; SAMUELS B; GIRALT S; RODRIGUEZ A; PRZEPIORKA D; MCLAUGHLIN P; ANDERSSON B; CLAXTON D; MIRZA N; MEHRA R; HAGEMEISTER F; CABANILLAS F; CHAMPLIN R
      PRELIMINARY-REPORT OF A NEW ACTIVE REGIMEN FOR AGGRESSIVE MANTLE CELLLYMPHOMA

      British Journal of Haematology
    45. RATANATHARATHORN V; NASH RA; PRZEPIORKA D; DEVINE SM; KLEIN JL; WEISDORF D; FAY JW; NADEMANEE A; ANTIN JH; CHRISTIANSEN NP; VANDERJAGT R; HERZIG RH; LITZOW MR; WOLFF SN; LONGO WL; PETERSEN FB; KARANES C; AVALOS B; STORB R; BUELL DN; MAHER RM; FITZSIMMONS WE; WINGARD JR
      PHASE-III STUDY COMPARING METHOTREXATE AND TACROLIMUS (PROGRAF, FK506) WITH METHOTREXATE AND CYCLOSPORINE FOR GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS AFTER HLA-IDENTICAL SIBLING BONE-MARROW TRANSPLANTATION

      Blood
    46. PRZEPIORKA D; PHILLIPS GL; RATANATHARATHORN V; COTTLERFOX M; SEHN LH; ANTIN JH; LEBHERZ D; AWWAD M; HOPE J; MCCLAIN JB
      A PHASE-II STUDY OF BTI-322, A MONOCLONAL ANTI-CD2 ANTIBODY, FOR TREATMENT OF STEROID-RESISTANT ACUTE GRAFT-VERSUS-HOST DISEASE

      Blood
    47. MARINI FC; SNELL V; LU J; PRZEPIORKA D; KORNBLAU SM
      VARIABLE CHANGES IN LYMPHOCYTE SUBSET COMPOSITION (LSC) OCCUR DURING PRODUCTION OF HUMAN SUICIDAL LYMPHOCYTES - IMPLICATIONS FOR CLINICAL-TRIALS

      Cancer gene therapy
    48. GIRALT S; WEBER D; COLOME M; DIMOPOULOS M; MEHRA R; VANBESIEN K; GAJEWSKI J; ANDERSSON B; KHOURI I; PRZEPIORKA D; VONWOLFF B; DELASALLE K; KORBLING M; SEONG D; ALEXANIAN R; CHAMPLIN R
      PHASE-I TRIAL OF CYCLOSPORINE-INDUCED AUTOLOGOUS GRAFT-VERSUS-HOST DISEASE IN PATIENTS WITH MULTIPLE-MYELOMA UNDERGOING HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM-CELL RESCUE

      Journal of clinical oncology
    49. IPPOLITI C; CHAMPLIN R; BUGAZIA N; PRZEPIORKA D; NEUMANN J; GIRALT S; KHOURI I; GAJEWSKI J
      USE OF OCTREOTIDE IN THE SYMPTOMATIC MANAGEMENT OF DIARRHEA INDUCED BY GRAFT-VERSUS-HOST DISEASE IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES

      Journal of clinical oncology
    50. KHOURI I; KEATING M; KORBLING M; PRZEPIORKA D; ANDERLINI P; OBRIEN S; VONWOLFF B; GIRALT S; GAJEWSKI J; MEHRA R; KANTARJIAN H; CHAMPLIN R
      INDUCTION OF GRAFT-VERSUS-LEUKEMIA USING FLUDARABINE-BASED ALLOGENEICMINI-TRANSPLANTS AS TREATMENT FOR LYMPHOID MALIGNANCIES

      Experimental hematology
    51. IPPOLITI C; MORGAN A; WARKENTIN D; VANBESIEN K; MEHRA R; KHOURI I; GIRALT S; GAJEWSKI J; CHAMPLIN R; ANDERSSON B; PRZEPIORKA D
      FOSCARNET FOR PREVENTION OF CYTOMEGALOVIRUS-INFECTION IN ALLOGENEIC MARROW TRANSPLANT RECIPIENTS UNABLE TO RECEIVE GANCICLOVIR

      Bone marrow transplantation
    52. WOO M; PRZEPIORKA D; IPPOLITI C; WARKENTIN D; KHOURI I; FRITSCHE H; KORBLING M
      TOXICITIES OF TACROLIMUS AND CYCLOSPORINE-A AFTER ALLOGENEIC BLOOD STEM-CELL TRANSPLANTATION

      Bone marrow transplantation
    53. PRZEPIORKA D; JAECKLE KA; BIRDWELL RR; FULLER GN; KUMAR AJ; HUH YO; MCCUTCHEON I
      SUCCESSFUL TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY WITH LOW-DOSE INTERLEUKIN-2

      Bone marrow transplantation
    54. WINGARD JR; NASH RA; RATANATHARATHORN V; FAY JW; KLEIN JL; PRZEPIORKA D; MAHER RM; DEVINE SM; BOSWELL G; BEKERSKY I; FITZSIMMONS W
      LACK OF INTERACTION BETWEEN TACROLIMUS (FK506) AND METHOTREXATE IN BONE-MARROW TRANSPLANT RECIPIENTS

      Bone marrow transplantation
    55. WOO MH; IPPOLITI C; BRUTON J; MEHRA R; CHAMPLIN R; PRZEPIORKA D
      HEADACHE, CIRCUMORAL PARESTHESIA, AND FACIAL FLUSHING ASSOCIATED WITHHIGH-DOSE CARMUSTINE INFUSION

      Bone marrow transplantation
    56. PRZEPIORKA D; ANDERLINI P; IPPOLITI C; KHOURI I; FIETZ T; THALL P; MEHRA R; GIRALT S; GAJEWSKI J; DEISSEROTH AB; CLEARY K; CHAMPLIN R; VANBESIEN K; ANDERSSON B; KORBLING M
      ALLOGENEIC BLOOD STEM-CELL TRANSPLANTATION IN ADVANCED HEMATOLOGIC CANCERS

      Bone marrow transplantation
    57. DELIMA M; VANBESIEN KW; GIRALT SA; KHOURI IF; MEHRA R; ANDERSSON BS; PRZEPIORKA D; GAJEWSKI JL; KORBLING M; CHAMPLIN RE
      BONE-MARROW TRANSPLANTATION AFTER FAILURE OF AUTOLOGOUS TRANSPLANT FOR NON-HODGKINS-LYMPHOMA

      Bone marrow transplantation
    58. VANBESIEN KW; DELIMA M; GIRALT SA; MOORE DF; KHOURI IF; RONDON G; MEHRA R; ANDERSSON BS; DYER C; CLEARY K; PRZEPIORKA D; GAJEWSKI JL; CHAMPLIN RE
      MANAGEMENT OF LYMPHOMA RECURRENCE AFTER ALLOGENEIC TRANSPLANTATION - THE RELEVANCE OF GRAFT-VERSUS-LYMPHOMA EFFECT

      Bone marrow transplantation
    59. NICHOLSON VA; WHIMBEY E; CHAMPLIN R; ABISAID D; PRZEPIORKA D; TARRAND J; CHAN K; BODEY GP; GOODRICH JM
      COMPARISON OF CYTOMEGALOVIRUS ANTIGENEMIA AND SHELL VIAL CULTURE IN ALLOGENEIC MARROW TRANSPLANTATION RECIPIENTS RECEIVING GANCICLOVIR PROPHYLAXIS

      Bone marrow transplantation
    60. ANDERLINI P; PRZEPIORKA D; SEONG C; SMITH TL; HUH YO; LAUPPE J; CHAMPLIN R; KORBLING M
      FACTORS AFFECTING MOBILIZATION OF CD34+ CELLS IN NORMAL DONORS TREATED WITH FILGRASTIM

      Transfusion
    61. ANDERLINI P; PRZEPIORKA D; SEONG D
      CLINICAL TOXICITY AND LABORATORY EFFECTS OF GRANULOCYTE-COLONY-STIMULATING FACTOR (FILGRASTIM) MOBILIZATION AND BLOOD STEM-CELL APHERESIS FROM NORMAL DONORS, AND ANALYSIS OF CHARGES FOR THE PROCEDURES (VOL 36,PG 590, 1996)

      Transfusion
    62. JAECKLE KA; PRZEPIORKA D; BIRDWELL RR; MCCUTCHEON I; FULLER GN
      FAVORABLE RESPONSE OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) TO TREATMENT WITH INTERLEUKIN-2

      Neurology
    63. ROWLINGS PA; PRZEPIORKA D; KLEIN JP; GALE RP; PASSWEG JR; HENSLEEDOWNEY PJ; CAHN JY; CALDERWOOD S; GRATWOHL A; SOCIE G; ABECASIS MM; SOBOCINSKI KA; ZHANG MJ; HOROWITZ MM
      IBMTR SEVERITY INDEX FOR GRADING ACUTE GRAFT-VERSUS-HOST DISEASE - RETROSPECTIVE COMPARISON WITH GLUCKSBERG GRADE

      British Journal of Haematology
    64. KHOURI IF; PRZEPIORKA D; VANBESIEN K; OBRIEN S; PALMER JL; LERNER S; MEHRA RC; VRIESENDORP HM; ANDERSSON BS; GIRALT S; KORBLING M; KEATING MJ; CHAMPLIN RE
      ALLOGENEIC BLOOD OR MARROW TRANSPLANTATION FOR CHRONIC LYMPHOCYTIC-LEUKEMIA - TIMING OF TRANSPLANTATION AND POTENTIAL EFFECT OF FLUDARABINEON ACUTE GRAFT-VERSUS-HOST DISEASE

      British Journal of Haematology
    65. ANDERLINI P; PRZEPIORKA D; LAUPPE J; SEONG D; GIRALT S; CHAMPLIN R; KORBLING M
      COLLECTION OF PERIPHERAL-BLOOD STEM-CELLS FROM NORMAL DONORS 60 YEARSOF AGE OR OLDER

      British Journal of Haematology
    66. ANDERLINI P; LAUPPE J; PRZEPIORKA D; SEONG D; CHAMPLIN R; KORBLING M
      PERIPHERAL-BLOOD STEM-CELL APHERESIS IN NORMAL DONORS - FEASIBILITY AND YIELD OF 2ND COLLECTIONS

      British Journal of Haematology
    67. ANDERLINI P; KORBLING M; DALE D; GRATWOHL A; SCHMITZ N; STRONCEK D; HOWE C; LEITMAN S; HOROWITZ M; GLUCKMAN E; ROWLEY S; PRZEPIORKA D; CHAMPLIN R
      ALLOGENEIC BLOOD STEM-CELL TRANSPLANTATION - CONSIDERATIONS FOR DONORS

      Blood
    68. DELIMA M; GIRALT S; GAJEWSKI J; KHOURI I; ANDERSSON B; VANBESIEN K; PRZEPIORKA D; MEHRA R; KORBLING M; CHAMPLIN R
      PILOT-STUDY OF HIGH-DOSE MELPHALAN AND ALLOGENEIC PERIPHERAL-BLOOD STEM-CELLS TRANSPLANTATION FOR TREATMENT OF RELAPSE POST ALLOGENEIC BLOOD AND MARROW TRANSPLANTATION

      Blood
    69. PRZEPIORKA D; GIRALT S; KHOURI I; CHAMPLIN R; BUESORAMOS C
      ALLOGENEIC MARROW TRANSPLANTATION FOR CHRONIC MYELOPROLIFERATIVE DISORDERS

      Blood
    70. KORNBLAU SM; MARINI FC; SNELL V; LU J; GEE A; DURRETT A; PRZEPIORKA D
      PRODUCTION OF HUMAN SUICIDAL LYMPHOCYTES INDUCES VARIABLE CHANGES IN LYMPHOCYTE SUBSET COMPOSITION (LSC) - POTENTIAL IMPLICATIONS FOR GENE-THERAPY TRIALS

      Blood
    71. FAYAD L; PRZEPIORKA D; FOLLODER J; KHOURI I; ANDERLINI P; KORBLING M; CHAMPLIN R; LICHTIGER B
      THE RISK OF ENGRAFTMENT-RELATED HEMOLYSIS IS NOT GREATER AFTER ABO-MISMATCHED ALLOGENEIC BLOOD STEM-CELL RATHER THAN MARROW TRANSPLANTATION

      Blood
    72. KONOPLEVA M; MIKHAIL A; ESTROV Z; ZHAO S; HARRIS D; SANCHEZWILLIAMS G; KORNBLAU S; JUNG J; KLICHE KO; JIANG S; PRZEPIORKA D; SNODGRASS HR; ESTEY E; ANDREEFF M
      A FUNCTIONAL RECEPTOR IN AML - CORRELATION OF EXPRESSION WITH BLAST COUNT AND FAB M1

      Blood
    73. PRZEPIORKA D; ANDERLINI P; IPPOLITI C; KHOURI I; FOLLODER J; UENO N; MEHRA R; GIRALT S; GAJEWSKI J; CLEARY K; CLAXTON D; ANDERSSON B; KORBLING M; CHAMPLIN R
      RISK-FACTORS FOR ACUTE GRAFT-VERSUS-HOST DISEASE IN ALLOGENEIC BLOOD STEM-CELL TRANSPLANT RECIPIENTS

      Blood
    74. HOFF M; GIRALT S; HUH Y; RONDON G; GAJEWSKI J; UENO N; CLAXTON D; MIRZA N; DAVIS M; VANBASIEN K; KHOURI I; REHRA R; PRZEPIORKA D; KORBLING M; TALPAZ M; KANTARJIAN H; CHAMPLIN R
      LONG-TERM FOLLOW-UP OF CD8-DEPLETED DONOR LYMPHOCYTE INFUSION (DLI) -AN EFFECTIVE TREATMENT FOR RELAPSED CHRONIC MYELOGENOUS LEUKEMIA (CML) AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION (BMT)

      Blood
    75. KIENAST J; IPPOLITI C; MEHRA R; UENO N; CHAMPLIN R; KHOURI I; GIRALT S; GAJEWSKI J; CLAXTON D; ANDERLINI P; ANDERSSON B; PRZEPIORKA D
      DOSE-INTENSIFIED ANTITHYMOCYTE GLOBULIN (ATG) IN STEROID-RESISTANT GRAFT-VERSUS-HOST DISEASE (GVHD) AFTER ALLOGENEIC MARROW OR BLOOD STEM-CELL TRANSPLANTATION

      Blood
    76. ILDSTAD ST; CRILLEY PA; SHADDUCK RK; KAUFMAN CL; MIRRO J; BRODSKY I; BRUGGER W; GAJEWSKI JL; PRZEPIORKA D; STYLER MJ; LISTER J; TOPOLSKY DL; MANZ M; KANZ L; CHAMPLIN RL
      GRAFT ENGINEERING - THE FACILITATING CELL (FC) PROTOCOL IN HLA MISMATCHED BMT FOR HEMATOLOGIC MALIGNANCY

      Blood
    77. POPAT U; ANDERSSON BS; VANBESIEN K; SMITH T; AMIN K; HUGHES P; FAHMI H; GIRALT S; MEHRA R; PRZEPIORKA D; KHOURI I; GAJEWSKI J; CLAXTON D; RODRIGUEZ M; ROMAGUERA J; HAGEMEISTER F; CABANILLAS F; CHAMPLIN RE
      ABMT IN RECURRENT OR REFRACTORY HD - LONG-TERM RESULTS

      Blood
    78. GARDERET L; SNELL V; PRZEPIORKA D; LU JG; ANDREEFF M; CHAMPLIN R
      EFFECTIVE REMOVAL OF ALLOREACTIVE LYMPHOCYTES FROM PERIPHERAL-BLOOD MONONUCLEAR CELL PREPARATIONS BY IMMUNOMAGNETIC CD25 DEPLETION

      Blood
    79. KORBLING M; MIRZA N; PRZEPIORKA D; ANDERLINI P; CHAN KW; CHAMPLIN R
      CLINICAL OUTCOME IN 112 PATIENTS FOLLOWING HLA-IDENTICAL ALLOGENEIC PERIPHERAL-BLOOD STEM-CELL (PBSC) TRANSPLANTATION

      Blood
    80. ANDERSSON BS; HAI T; MADDEN T; CAGNONI P; JONES R; BRUTON J; MARTINKA S; HOLBERT K; GIRALT S; PRZEPIORKA D; LENNON S; SPILKER B; GIAN V; WINGARD J; TARANTOLO S; KASHYAP A; FORMAN S; CHAMPLIN RE
      ALLOGENEIC TRANSPLANTATION IN ADVANCED HEMATOLOGIC MALIGNANCIES AFTER-IV BUSULFAN CYCLOFOSFAMIDE (BUCY)

      Blood
    81. KHOURI I; KANTARJIAN JR; PUGH W; PALMER J; PRZEPIORKA D; RODRIGUEZ A; SAMUELS B; GIRALT S; GAJEWSKI J; MEHRA R; HAGEMEISTER F; CABANILLAS F; CHAMPLIN R
      PRELIMINARY-REPORT OF AN ACTIVE REGIMEN FOR MANTLE CELL LYMPHOMA (MCL)

      Blood
    82. GIRALT S; MIRZA N; MEHRA R; GAJEWSKI J; ANDERSSON B; PRZEPIORKA D; KHOURI I; KORBLING M; COHEN A; RAHMAN Z; VANBESIEN K; IPPOLITI C; BRUTON J; ANDERLINI P; UENO N; CHAMPLIN R
      RESULTS OF CD8 DEPLETED ALLOGENEIC PERIPHERAL-BLOOD STEM-CELL TRANSPLANTATION (CD8- ALLO-PBSC) FOR CHRONIC MYELOGENOUS LEUKEMIA (CML)

      Blood
    83. GIRALT S; COHEN A; MEHRA R; GAJEWSKI J; ANDERSSON B; PRZEPIORKA D; KHOURI I; KORBLING M; DAVIS M; VANBESIEN K; IPPOLITI C; BRUTON J; ANDERLINI P; UENO N; CHAMPLIN R
      PRELIMINARY-RESULTS OF FLUDARABINE MELPHALAN OR 2CDA/MELPHALAN (2CDA/M) AS PREPARATIVE REGIMENS FOR ALLOGENEIC PROGENITOR-CELL TRANSPLANTATION (ALLO-PCT) IN POOR CANDIDATES FOR CONVENTIONAL MYELOABLATIVE CONDITIONING/

      Blood
    84. GIRALT S; GAJEWSKI J; KHOURI I; KORBLING M; CLAXTON D; MEHRA R; PRZEPIORKA D; ANDERSSON B; TALPAZ M; KANTARJIAN H; CHAMPLIN R
      INDUCTION OF GRAFT-VS-LEUKEMIA (GVL) AS PRIMARY-TREATMENT OF CHRONIC MYELOGENOUS LEUKEMIA (CML)

      Blood
    85. NASH RA; ANTIN J; KARANES C; FAY J; AVALOS B; YEAGER AM; PRZEPIORKA D; DAVIES S; PETERSEN F; BUELL D; FITZSIMMONS W; BARTELS P; HANSEN J; ANASETTI C; STORB R; RATANATHARATHORN V
      PHASE-III STUDY COMPARING TACROLIMUS (FK506) WITH CYCLOSPORINE (CSP) FOR PROPHYLAXIS OF ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) AFTER MARROWTRANSPLANTATION FROM UNRELATED DONORS

      Blood
    86. KHOURI I; ROMAGUERA J; KANTARJIAN H; PUGH W; PALMER J; PRZEPIORKA D; RODRIGUEZ A; SAMUELS B; GIRALT S; GAJEWSKI J; MEHRA R; HAGEMEISTER F; CABANILLAS F; CHAMPLIN R
      MANTLE CELL LYMPHOMA (MCL) - IMPROVED OUTCOME WITH HYPER-CVAD HIGH DOSE METHOTREXATE-CYTARABINE (MTX-ARA-C) FOLLOWED BY AUTOLOGOUS OR ALLOGENEIC STEM-CELL TRANSPLANTATION (SCT)/

      Blood
    87. GIRALT S; ESTEY E; ALBITAR M; VANBESIEN K; RONDON G; ANDERLINI P; OBRIEN S; KHOURI I; GAJEWSKI J; MEHRA R; CLAXTON D; ANDERSSON B; BERAN M; PRZEPIORKA D; KOLLER C; KORNBLAU S; KORBLING M; KEATING M; KANTARJIAN H; CHAMPLIN R
      ENGRAFTMENT OF ALLOGENEIC HEMATOPOIETIC PROGENITOR CELLS WITH PURINE ANALOG-CONTAINING CHEMOTHERAPY - HARNESSING GRAFT-VERSUS-LEUKEMIA WITHOUT MYELOABLATIVE THERAPY

      Blood
    88. PRZEPIORKA D; LICHTIGER B
      TO THE EDITOR - REPLY

      American journal of clinical pathology
    89. LEWIS VA; CHAMPLIN R; ENGLUND J; COUCH R; GOODRICH JM; ROLSTON K; PRZEPIORKA D; MIRZA NQ; YOUSUF HM; LUNA M; BODEY GP; WHIMBEY E
      RESPIRATORY-DISEASE DUE TO PARAINFLUENZA VIRUS IN ADULT BONE-MARROW TRANSPLANT RECIPIENTS

      Clinical infectious diseases
    90. WHIMBEY E; CHAMPLIN RE; COUCH RB; ENGLUND JA; GOODRICH JM; RAAD I; PRZEPIORKA D; LEWIS VA; MIRZA N; YOUSUF H; TARRAND JJ; BODEY GP
      COMMUNITY RESPIRATORY VIRUS-INFECTIONS AMONG HOSPITALIZED ADULT BONE-MARROW TRANSPLANT RECIPIENTS

      Clinical infectious diseases
    91. VANBESIEN K; PRZEPIORKA D; MEHRA R; GIRALT S; KHOURI I; GAJEWSKI J; ANDERSSON B; CHAMPLIN R
      IMPACT OF PREEXISTING CNS INVOLVEMENT ON THE OUTCOME OF BONE-MARROW TRANSPLANTATION IN ADULT HEMATOLOGIC MALIGNANCIES

      Journal of clinical oncology
    92. KHOURI IF; IPPOLITI C; GAJEWSKI J; PRZEPIORKA D; CHAMPLIN RE
      NEUTROPENIAS FOLLOWING ALLOGENEIC BONE-MARROW TRANSPLANTATION - RESPONSE TO THERAPY WITH HIGH-DOSE INTRAVENOUS IMMUNOGLOBULIN

      American journal of hematology
    93. PRZEPIORKA D; ESTEY E
      WHEN IS SELECTION BIAS NOT SELECTION BIAS

      American journal of hematology
    94. ANDERLINI P; PRZEPIORKA D; SEONG D; CHAMPLIN R; KORBLING M
      AN ANALYSIS OF FACTORS CORRELATED WITH THE COLLECTION OF PERIPHERAL-BLOOD PROGENITOR CELLS (PBPCS) FROM NORMAL DONORS

      Experimental hematology
    95. ANDERLINI P; PRZEPIORKA D; SEONG D; CHAMPLIN R; KORBLING M
      TRANSIENT NEUTROPENIA IN NORMAL DONORS AFTER G-CSF MOBILIZATION AND STEM-CELL APHERESIS

      Experimental hematology
    96. GAJEWSKI J; CECKA M; GJERTSON D; PETZ L; PRZEPIORKA D; VANBESIEN K; GIRALT S; SCHILLER G; FEIG S; CHAN K; LILL M; TERRITO M; TERASKI P; CHAMPLIN R
      MULTIVARIATE-ANALYSIS OF ABDR SEROLOGICAL MATCHED UNRELATED DONOR BONE-MARROW TRANSPLANT DEMONSTRATES DNA MATCHING FOR DR-BETA-1 AND DQ-BETA-1 ALLELES IMPROVE OUTCOMES

      Experimental hematology
    97. KORBLING M; ANDERLINI P; DURETT A; MAADANI F; BOJKO P; SEONG D; GIRALT S; KHOURI I; ANDERSSON B; MEHRA R; VANBESIEN K; MIRZA N; PRZEPIORKA D; CHAMPLIN R
      DELAYED-EFFECTS OF RHG-CSF MOBILIZATION TREATMENT AND APHERESIS ON CIRCULATING CD34(-1(DIM) CD38(-) PROGENITOR CELLS, AND LYMPHOID SUBSETS IN NORMAL STEM-CELL DONORS FOR ALLOGENEIC TRANSPLANTATION() AND CD34(+) THY)

      Bone marrow transplantation
    98. KORBLING M; CHAN KW; ANDERLINI P; SEONG D; DURETT A; LANGLINAIS A; PRZEPIORKA D; GAJEWSKI J; MILLER P; SUNDBERG J; ALILAEN P; BOJKO P; MIRZA N; CLAXTON D; VANBESIEN K; KHOURI I; ANDERSSON B; MEHRA R; CHAMPLIN R
      ALLOGENEIC PERIPHERAL-BLOOD STEM-CELL TRANSPLANTATION USING NORMAL PATIENT-RELATED PEDIATRIC DONORS

      Bone marrow transplantation
    99. MCCARTHY PL; WILLIAMS L; HARRISBACILE M; YEN J; PRZEPIORKA D; IPPOLITI C; CHAMPLIN R; FAY J; BLOSCH C; JACOBS C; ANASETTI C
      A CLINICAL-PHASE I II STUDY OF RECOMBINANT HUMAN INTERLEUKIN-1 RECEPTOR IN GLUCOCORTICOID-RESISTANT GRAFT-VERSUS-HOST DISEASE/

      Transplantation
    100. PRZEPIORKA D; IPPOLITI C; KHOURI I; ANDERLINI P; MEHRA R; GIRALT S; GAJEWSKI J; FRITSCHE H; DEISSEROTH AB; CLEARY K; CHAMPLIN R; VANBESIEN K; ANDERSSON B; KORBLING M
      ALLOGENEIC TRANSPLANTATION FOR ADVANCED LEUKEMIA - IMPROVED SHORT-TERM OUTCOME WITH BLOOD STEM-CELL GRAFTS AND TACROLIMUS

      Transplantation


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/06/20 alle ore 06:26:29